Currently, there are 290.82M common shares owned by the public and among those 206.32M shares have been available to trade.
The company’s stock has a 5-day price change of 1.44% and -37.19% over the past three months. ABCL shares are trading -50.61% year to date (YTD), with the 12-month market performance down to -56.68% lower. It has a 12-month low price of $2.66 and touched a high of $8.05 over the same period. ABCL has an average intraday trading volume of 1.59 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.48%, -19.89%, and -36.90% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of AbCellera Biologics Inc (NASDAQ: ABCL) shares accounts for 38.64% of the company’s 290.82M shares outstanding.
It has a market capitalization of $829.22M and a beta (3y monthly) value of 0.38. The earnings-per-share (ttm) stands at -$0.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.67% over the week and 5.01% over the month.
Earnings per share for the fiscal year are expected to increase by 6.32%, and -6.14% over the next financial year.
Looking at the support for the ABCL, a number of firms have released research notes about the stock. The Benchmark Company stated their Buy rating for the stock in a research note on February 22, 2024, with the firm’s price target at $9. KeyBanc Capital Markets coverage for the AbCellera Biologics Inc (ABCL) stock in a research note released on December 05, 2023 offered a Overweight rating with a price target of $6. The Benchmark Company was of a view on November 06, 2023 that the stock is Hold, while Piper Sandler gave the stock Overweight rating on October 13, 2023, issuing a price target of $20. Cowen on their part issued Outperform rating on February 28, 2023.
